Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol

This publication has 45 references indexed in Scilit:

• Dose-Response Relationships of Serum Lipid Measurements With the Extent of Coronary Stenosis
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
• The Role of Lipoprotein A-I and Lipoprotein A-I/A-II in Predicting Coronary Artery Disease
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
• Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men
  The American Journal of Cardiology, 1992
• Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II — DAVIT II)
  The American Journal of Cardiology, 1990
• Verapamil
  Drugs, 1989
• Lipids, diabetes, and coronary heart disease: Insights from the Framingham Study
  American Heart Journal, 1985
• Atherosclerosis, calcium, and calcium antagonists.
  Circulation, 1985
• Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease
  The American Journal of Cardiology, 1985
• Beta blockade during and after myocardial infarction: An overview of the randomized trials
  Progress in Cardiovascular Diseases, 1985
• Effect of Verapamil on Serum Lipoproteins in Patients with Angina Pectoris
  Acta Medica Scandinavica, 1984